Drugs / hepatitis B immune globin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01878565 | Jun 2013 → Dec 2014 | chronic hepatitis B virus infection | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hepatitis B immune globin | “hepatitis B immune globin (HBIG)+granulocyte-macrophage colony-stimulating factor (GM-CSF)+HBV vaccine” NCT01878565 ↗ |
| Known as | HBIG | “the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4” NCT01878565 ↗ |
| Action | Inhibit | “initial HBIG injection possibly reduces HBsAg” NCT01878565 ↗ |
| Modality | Protein / enzyme biologic | “hepatitis B immune globin (HBIG)” NCT01878565 ↗ |
| Route | Intramuscular | “800 unit of HBIG intramuscularly” NCT01878565 ↗ |